How should orthostatic hypotension be managed, including lifestyle measures and first-line medication?

Management of Orthostatic Hypotension

Begin with non-pharmacological measures including 2-3 L fluid intake daily, 10 g NaCl daily, head-up tilt sleeping at 10°, compression garments, and physical counterpressure maneuvers; if symptoms persist, add midodrine (5-20 mg three times daily) as first-line pharmacological therapy, with fludrocortisone (0.1-0.3 mg once daily) as an alternative or adjunctive agent. 1, 2

Stepwise Treatment Algorithm

Step 1: Medication Review and Elimination

• Immediately discontinue or reduce medications exacerbating orthostatic hypotension including psychotropic drugs, diuretics, α-adrenoreceptor antagonists, and tricyclic antidepressants 2
• Correct volume depletion from any underlying cause 2

Step 2: Non-Pharmacological Interventions (First-Line for All Patients)

Volume Expansion:

• Fluid intake: 2-3 L daily 1
• Salt intake: 10 g NaCl daily via high-salt foods, salt tablets, or sachets 1
• Rapid cool water ingestion (acute relief) 1

Postural Modifications:

• Sleep with head of bed elevated 10° to prevent nocturnal polyuria, maintain favorable fluid distribution, and ameliorate nocturnal hypertension 1, 2
• Gradual staged movements with postural changes 2
• Avoid large carbohydrate-rich meals (reduces postprandial hypotension) 2

Mechanical Countermeasures:

• Compression stockings (waist-high) or abdominal binders to reduce venous pooling 1, 2, 3
• Physical counterpressure maneuvers: leg crossing, squatting, muscle tensing when symptomatic 1, 2, 3

Step 3: Pharmacological Therapy (When Non-Pharmacological Measures Insufficient)

First-Line Medication:

Midodrine (α1-adrenergic agonist):

• Dosing: 5-20 mg three times daily 1, 2
• Take first dose before arising; avoid several hours before planned recumbency 2
• Evidence: Three randomized placebo-controlled trials demonstrate efficacy 1
• FDA-approved for symptomatic orthostatic hypotension 2
• Mechanism: Arteriolar constriction and venoconstriction 2
• Adverse effects: Pilomotor reactions, pruritus, supine hypertension, bradycardia, GI symptoms, urinary retention 2
• Most beneficial in patients with hypotensive phenotype 4

Alternative First-Line Medication:

Fludrocortisone (mineralocorticoid):

• Dosing: Start 0.05-0.1 mg daily, titrate to 0.1-0.3 mg once daily 1, 2, 3
• Mechanism: Sodium retention, fluid volume expansion, direct vessel constriction 1, 2
• Evidence: Two small observational studies plus one double-blind trial (60 patients) showing symptomatic benefit 1
• Adverse effects: Supine hypertension, hypokalemia, congestive heart failure, peripheral edema 2

Combination Therapy:

• Use midodrine plus fludrocortisone in non-responders to monotherapy 2

Step 4: Additional Pharmacological Options (Refractory Cases)

Droxidopa:

• FDA-approved alternative to midodrine 5, 3, 6
• Beneficial in neurogenic orthostatic hypotension 3

Pyridostigmine:

• Advantage: No risk of fluid retention or supine hypertension 5, 3
• Consider in patients with cardiac involvement who cannot tolerate volume expansion 5
• May be beneficial in refractory cases 3

Specialized Therapies (Context-Specific):

• Desmopressin: For nocturnal polyuria and morning orthostatic hypotension 1, 2
• Octreotide: For postprandial hypotension 1, 3
• Erythropoietin: In diabetic patients with hemoglobin <11 g/dL (25-75 U/kg three times weekly, target Hgb 12 g/dL) 2

Critical Management Considerations

Supine Hypertension Challenge

This is the most common pitfall in orthostatic hypotension management. The therapeutic goal is symptom minimization, not normotension restoration 2. Balance standing BP improvement against supine hypertension risk 2:

• Avoid midodrine doses several hours before recumbency 2
• Head-up tilt sleeping ameliorates nocturnal hypertension 1
• Monitor both supine and standing BP regularly 2

Treatment Goals

• Primary goal: Symptom relief and fall prevention, NOT blood pressure targets 6
• Minimize postural symptoms rather than restore normotension 2
• Improve quality of life and standing time 2

Evidence Quality Considerations

The 2011 diabetes guidelines 2 provide the most comprehensive treatment recommendations with specific evidence levels: midodrine has Level A evidence, fludrocortisone has Level B evidence, and non-pharmacological measures have Level B evidence. The 2009 ESC syncope guidelines 1 corroborate these recommendations with three randomized controlled trials supporting midodrine efficacy.

Special Populations

Diabetic patients with cardiovascular autonomic neuropathy: All medications except pyridostigmine may be poorly tolerated in patients with cardiac restrictive physiology 5. Exercise caution with volume expansion strategies in heart failure patients 5.